CG Oncology, Inc. Common stock (CGON)vsVertex Pharmaceuticals Inc (VRTX)
CGON
CG Oncology, Inc. Common stock
$73.03
+5.66%
HEALTHCARE · Cap: $6.19B
VRTX
Vertex Pharmaceuticals Inc
$481.70
-0.34%
HEALTHCARE · Cap: $119.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 240839% more annual revenue ($12.22B vs $5.07M). VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
CGON
Avoid32
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CGON.
Margin of Safety
+49.1%
Fair Value
$941.26
Current Price
$481.70
$459.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 1983.0% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -17.1% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CGON
The strongest argument for CGON centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 1983.0% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : CGON
The primary concerns for CGON are EPS Growth, Profit Margin, Piotroski F-Score.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CGON profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
VRTX carries more volatility with a beta of 0.29 — expect wider price swings.
CGON is growing revenue faster at 1983.0% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 32/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CG Oncology, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070, an oncolytic virus therapy designed for non-muscle invasive bladder cancer. The company is well-positioned to meet significant unmet medical needs in oncology, emphasizing the potential to improve patient outcomes and transform treatment approaches. With a robust proprietary technology platform and a commitment to advancing clinical trials and securing regulatory approvals, CG Oncology represents a compelling investment opportunity for institutional investors interested in pioneering advancements in cancer care.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?